Matches in SemOpenAlex for { <https://semopenalex.org/work/W2902611029> ?p ?o ?g. }
Showing items 1 to 94 of
94
with 100 items per page.
- W2902611029 endingPage "415" @default.
- W2902611029 startingPage "415" @default.
- W2902611029 abstract "1761 Inhibition of angiogenesis is currently perceived as one of the promising strategies in the cancer therapy. Thalidomide (Thalomid®) and its Immunomodulatory Drug (IMiD®) analogs have entered into clinical trials for the treatment of various types of cancers. Lenalidomide (Revlimid®, CC-5013) is currently being assessed in oncology clinical trials worldwide. In this study we have compared the anti-angiogenic mechanisms of thalidomide and lenalidomide in a variety of experimental systems representing distinct events of the angiogenic process. Endothelial cell (EC) proliferation is stimulated by growth factors. Neither thalidomide nor lenalidomide have an appreciable inhibitory effect on growth factor-induced proliferation of human umbilical vein endothelial cells (HUVEC). In both the HUVEC and B16-F10 mouse melanoma tube formation assays, lenalidomide appears to be at least 10-fold more potent than thalidomide, the latter indicating that effects extend to vessels lined by tumor cells. However, in endothelial cell migration assays, thalidomide is more active than lenalidomide; in both the HUVEC and B16-F10 monolayer scratch migration assays, thalidomide is clearly more potent than lenalidomide in preventing the migration of cells into the wounded/scratched region. In assays of HUVEC migration towards specific angiogenic factors, such as VEGF, bFGF, and TNF-α, thalidomide is also more potent than lenalidomide. Interestingly, assays where the whole physiological process of angiogenesis can be studied show differential sensitivities. Lenalidomide is more potent in the rat aorta assay, whereas thalidomide is more potent in the human umbilical explant assay. Mechanistic studies on signal transduction events triggered by VEGF show that both thalidomide and lenalidomide partially inhibit Akt phosphorylation in VEGF-induced HUVEC. Furthermore, inhibitory effects on the phosphorylation of Gab1, a scaffolding protein upstream of Akt activation, have been observed. In summary, our data indicate that both thalidomide and lenalidomide interfere with key events in the angiogenic process and that they can be differentiated qualitatively depending on which component part is studied." @default.
- W2902611029 created "2018-12-11" @default.
- W2902611029 creator A5017572254 @default.
- W2902611029 creator A5047250217 @default.
- W2902611029 creator A5060011858 @default.
- W2902611029 creator A5061079851 @default.
- W2902611029 creator A5061208744 @default.
- W2902611029 creator A5067606220 @default.
- W2902611029 creator A5078883724 @default.
- W2902611029 creator A5080542933 @default.
- W2902611029 date "2006-04-15" @default.
- W2902611029 modified "2023-09-23" @default.
- W2902611029 title "VEGFr inhibitor YN968D1 xenograft dose response studies against human colon cancer Ls174t and HT29" @default.
- W2902611029 hasPublicationYear "2006" @default.
- W2902611029 type Work @default.
- W2902611029 sameAs 2902611029 @default.
- W2902611029 citedByCount "1" @default.
- W2902611029 crossrefType "journal-article" @default.
- W2902611029 hasAuthorship W2902611029A5017572254 @default.
- W2902611029 hasAuthorship W2902611029A5047250217 @default.
- W2902611029 hasAuthorship W2902611029A5060011858 @default.
- W2902611029 hasAuthorship W2902611029A5061079851 @default.
- W2902611029 hasAuthorship W2902611029A5061208744 @default.
- W2902611029 hasAuthorship W2902611029A5067606220 @default.
- W2902611029 hasAuthorship W2902611029A5078883724 @default.
- W2902611029 hasAuthorship W2902611029A5080542933 @default.
- W2902611029 hasConcept C104317684 @default.
- W2902611029 hasConcept C121608353 @default.
- W2902611029 hasConcept C126322002 @default.
- W2902611029 hasConcept C134459356 @default.
- W2902611029 hasConcept C185592680 @default.
- W2902611029 hasConcept C202751555 @default.
- W2902611029 hasConcept C203014093 @default.
- W2902611029 hasConcept C25602115 @default.
- W2902611029 hasConcept C2776056115 @default.
- W2902611029 hasConcept C2776063141 @default.
- W2902611029 hasConcept C2776364478 @default.
- W2902611029 hasConcept C2777411675 @default.
- W2902611029 hasConcept C2778540781 @default.
- W2902611029 hasConcept C2779609412 @default.
- W2902611029 hasConcept C2780394083 @default.
- W2902611029 hasConcept C502942594 @default.
- W2902611029 hasConcept C55493867 @default.
- W2902611029 hasConcept C71924100 @default.
- W2902611029 hasConcept C98274493 @default.
- W2902611029 hasConceptScore W2902611029C104317684 @default.
- W2902611029 hasConceptScore W2902611029C121608353 @default.
- W2902611029 hasConceptScore W2902611029C126322002 @default.
- W2902611029 hasConceptScore W2902611029C134459356 @default.
- W2902611029 hasConceptScore W2902611029C185592680 @default.
- W2902611029 hasConceptScore W2902611029C202751555 @default.
- W2902611029 hasConceptScore W2902611029C203014093 @default.
- W2902611029 hasConceptScore W2902611029C25602115 @default.
- W2902611029 hasConceptScore W2902611029C2776056115 @default.
- W2902611029 hasConceptScore W2902611029C2776063141 @default.
- W2902611029 hasConceptScore W2902611029C2776364478 @default.
- W2902611029 hasConceptScore W2902611029C2777411675 @default.
- W2902611029 hasConceptScore W2902611029C2778540781 @default.
- W2902611029 hasConceptScore W2902611029C2779609412 @default.
- W2902611029 hasConceptScore W2902611029C2780394083 @default.
- W2902611029 hasConceptScore W2902611029C502942594 @default.
- W2902611029 hasConceptScore W2902611029C55493867 @default.
- W2902611029 hasConceptScore W2902611029C71924100 @default.
- W2902611029 hasConceptScore W2902611029C98274493 @default.
- W2902611029 hasLocation W29026110291 @default.
- W2902611029 hasOpenAccess W2902611029 @default.
- W2902611029 hasPrimaryLocation W29026110291 @default.
- W2902611029 hasRelatedWork W1528519698 @default.
- W2902611029 hasRelatedWork W1964370179 @default.
- W2902611029 hasRelatedWork W1992927350 @default.
- W2902611029 hasRelatedWork W1999464994 @default.
- W2902611029 hasRelatedWork W2008641990 @default.
- W2902611029 hasRelatedWork W2029990380 @default.
- W2902611029 hasRelatedWork W2113935263 @default.
- W2902611029 hasRelatedWork W2146001019 @default.
- W2902611029 hasRelatedWork W2161730969 @default.
- W2902611029 hasRelatedWork W2226803679 @default.
- W2902611029 hasRelatedWork W2249765072 @default.
- W2902611029 hasRelatedWork W2371305588 @default.
- W2902611029 hasRelatedWork W2415365722 @default.
- W2902611029 hasRelatedWork W2473526019 @default.
- W2902611029 hasRelatedWork W2507173626 @default.
- W2902611029 hasRelatedWork W2559102853 @default.
- W2902611029 hasRelatedWork W2765580283 @default.
- W2902611029 hasRelatedWork W2884112291 @default.
- W2902611029 hasRelatedWork W3075671293 @default.
- W2902611029 hasRelatedWork W749038731 @default.
- W2902611029 hasVolume "66" @default.
- W2902611029 isParatext "false" @default.
- W2902611029 isRetracted "false" @default.
- W2902611029 magId "2902611029" @default.
- W2902611029 workType "article" @default.